TY - JOUR AU - Chapman, A. B. AU - Devuyst, O. AU - Eckardt, K. U. AU - Gansevoort, R. T. AU - Harris, T. AU - Horie, S. PY - 2015 DA - 2015// TI - Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference JO - Kidney Int VL - 88 UR - https://doi.org/10.1038/ki.2015.59 DO - 10.1038/ki.2015.59 ID - Chapman2015 ER - TY - JOUR AU - Grantham, J. J. AU - Mulamalla, S. AU - Swenson-Fields, K. I. PY - 2011 DA - 2011// TI - Why kidneys fail in autosomal dominant polycystic kidney disease JO - Nat Rev Nephrol VL - 7 UR - https://doi.org/10.1038/nrneph.2011.109 DO - 10.1038/nrneph.2011.109 ID - Grantham2011 ER - TY - JOUR AU - Grantham, J. J. AU - Torres, V. E. AU - Chapman, A. B. AU - Guay-Woodford, L. M. AU - Bae, K. T. AU - King, B. F. PY - 2006 DA - 2006// TI - Volume progression in polycystic kidney disease JO - New Engl J of Med VL - 354 UR - https://doi.org/10.1056/NEJMoa054341 DO - 10.1056/NEJMoa054341 ID - Grantham2006 ER - TY - JOUR AU - Chapman, A. r. l. e. n. e. B. AU - Bost, J. a. m. e. s. E. AU - Torres, V. i. c. e. n. t. e. E. AU - Guay-Woodford, L. i. s. a. AU - Bae, K. y. o. n. g. t. a. e. T. y. AU - Landsittel, D. o. u. g. l. a. s. AU - Li, J. i. e. AU - King, B. e. r. n. a. r. d. F. AU - Martin, D. i. e. g. o. AU - Wetzel, L. o. u. i. s. H. AU - Lockhart, M. a. r. k. E. AU - Harris, P. e. t. e. r. C. AU - Moxey-Mims, M. a. r. v. a. AU - Flessner, M. i. k. e. AU - Bennett, W. i. l. l. i. a. m. M. AU - Grantham, J. a. r. e. d. J. PY - 2012 DA - 2012// TI - Kidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease JO - Clinical Journal of the American Society of Nephrology VL - 7 UR - https://doi.org/10.2215/CJN.09500911 DO - 10.2215/CJN.09500911 ID - Chapman2012 ER - TY - JOUR AU - Belibi, F. A. AU - Reif, G. AU - Wallace, D. P. AU - Yamaguchi, T. AU - Olsen, L. AU - Li, H. PY - 2004 DA - 2004// TI - Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells1 JO - Kidney Int VL - 66 UR - https://doi.org/10.1111/j.1523-1755.2004.00843.x DO - 10.1111/j.1523-1755.2004.00843.x ID - Belibi2004 ER - TY - JOUR AU - Wang, X. AU - Wu, Y. PY - 2008 DA - 2008// TI - Vasopressin directly regulates cyst growth in polycystic kidney disease JO - J Am SocNephrol VL - 19 ID - Wang2008 ER - TY - JOUR AU - Gattone, V. H. 2. n. d. 1. AU - Wang, X. PY - 2003 DA - 2003// TI - Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm935 DO - 10.1038/nm935 ID - Gattone2003 ER - TY - JOUR AU - Meijer, E. AU - Gansevoort, R. T. PY - 2011 DA - 2011// TI - Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug JO - Nephrol Dial Transplant VL - 26 UR - https://doi.org/10.1093/ndt/gfr069 DO - 10.1093/ndt/gfr069 ID - Meijer2011 ER - TY - JOUR AU - Torres, V. E. AU - Chapman, A. B. PY - 2012 DA - 2012// TI - Tolvaptan in patients with autosomal dominant polycystic kidney disease. TEMPO 3:4 trial investigators JO - N Engl J Med 20 VL - 367 UR - https://doi.org/10.1056/NEJMoa1205511 DO - 10.1056/NEJMoa1205511 ID - Torres2012 ER - TY - STD TI - Assessment report Jinarc International non-proprietary name: tolvaptan. Eur Med Agency. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002788/WC500187923.pdf. Accessed 10 Nov 2015. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002788/WC500187923.pdf ID - ref10 ER - TY - JOUR AU - Gansevoort, R. T. AU - Mustafa, A. PY - 2016 DA - 2016// TI - Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice JO - Nephrol Dial Trasplant VL - 31 UR - https://doi.org/10.1093/ndt/gfv456 DO - 10.1093/ndt/gfv456 ID - Gansevoort2016 ER - TY - JOUR AU - Watkins, P. B. 1. AU - Lewis, J. H. 2. PY - 2015 DA - 2015// TI - Clinical pattern of Tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database JO - Drug Saf VL - 38 UR - https://doi.org/10.1007/s40264-015-0327-3 DO - 10.1007/s40264-015-0327-3 ID - Watkins2015 ER - TY - JOUR AU - Gresser, U. PY - 2001 DA - 2001// TI - Amoxicillin-clavulanic acid therapy may be associated with severe side effects -- review of the literature JO - Eur J Med Res VL - 6 ID - Gresser2001 ER - TY - JOUR AU - Watkins, P. B. PY - 2017 DA - 2017// TI - Amoxicillin/clavulanic acid/tolvaptan JO - Reactions VL - 1655 ID - Watkins2017 ER -